Wednesday, February 10, 2016

Softer sell by Big Pharma's sales reps, says WSJ

Cutbacks in sales forces and time-strapped doctors have drug companies altering how they pitch products, the Wall Street Journal reports.

Softer sell by Big Pharma's sales reps, says WSJ


Now that Alcoa has kicked off earnings season, we're in that quiet period before the onslaught later this month of numbers, justifications and "wait till next year." (Which would be this year.)

What caught my attention as I scanned the usual news outlets was this: The Wall Street Journal reports on how sales reps for the pharmaceutical industry have changed their sales pitches. Will the softer sell work? Here's a link to the story.

In other news, Shire PLC isn't providing any details, but the British drug company with North American headquarters in Wayne, Pa., said it has acquired the U.S. rights to Resolor, a constipation treatment, from Janssen Pharmaceutica N.V.

Also, no terms were released as Abry Partners, a private-equity firm, invested in Conshohocken-based NSM Insurance Group, a 21-year-old firm that focuses on niche insurance products. The capital will be used to support acquisition and growth plans, NSM said.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter